Literature DB >> 12097581

Analysis of antigenicity and topology of E2 glycoprotein present on recombinant hepatitis C virus-like particles.

Reginald F Clayton1, Ania Owsianka, Jim Aitken, Susan Graham, David Bhella, Arvind H Patel.   

Abstract

Purification of hepatitis C virus (HCV) from sera of infected patients has proven elusive, hampering efforts to perform structure-function analysis of the viral components. Recombinant forms of the viral glycoproteins have been used instead for functional studies, but uncertainty exists as to whether they closely mimic the virion proteins. Here, we used HCV virus-like particles (VLPs) generated in insect cells infected with a recombinant baculovirus expressing viral structural proteins. Electron microscopic analysis revealed a population of pleomorphic VLPs that were at least partially enveloped with bilayer membranes and had viral glycoprotein spikes protruding from the surface. Immunogold labeling using specific monoclonal antibodies (MAbs) demonstrated these protrusions to be the E1 and E2 glycoproteins. A panel of anti-E2 MAbs was used to probe the surface topology of E2 on the VLPs and to compare the antigenicity of the VLPs with that of truncated E2 (E2(660)) or the full-length (FL) E1E2 complex expressed in mammalian cells. While most MAbs bound to all forms of antigen, a number of others showed striking differences in their abilities to recognize the various E2 forms. All MAbs directed against hypervariable region 1 (HVR-1) recognized both native and denatured E2(660) with comparable affinities, but most bound either weakly or not at all to the FL E1E2 complex or to VLPs. HVR-1 on VLPs was accessible to these MAbs only after denaturation. Importantly, a subset of MAbs specific for amino acids 464 to 475 and 524 to 535 recognized E2(660) but not VLPs or FL E1E2 complex. The antigenic differences between E2(660,) FL E1E2, and VLPs strongly point to the existence of structural differences, which may have functional relevance. Trypsin treatment of VLPs removed the N-terminal part of E2, resulting in a 42-kDa fragment. In the presence of detergent, this was further reduced to a trypsin-resistant 25-kDa fragment, which could be useful for structural studies.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12097581      PMCID: PMC136371          DOI: 10.1128/jvi.76.15.7672-7682.2002

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  61 in total

Review 1.  Biogenesis of hepatitis C virus envelope glycoproteins.

Authors:  Anne Op De Beeck; Laurence Cocquerel; Jean Dubuisson
Journal:  J Gen Virol       Date:  2001-11       Impact factor: 3.891

2.  Involvement of endoplasmic reticulum chaperones in the folding of hepatitis C virus glycoproteins.

Authors:  A Choukhi; S Ung; C Wychowski; J Dubuisson
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

3.  The transmembrane domains of hepatitis C virus envelope glycoproteins E1 and E2 play a major role in heterodimerization.

Authors:  A Op De Beeck; R Montserret; S Duvet; L Cocquerel; R Cacan; B Barberot; M Le Maire; F Penin; J Dubuisson
Journal:  J Biol Chem       Date:  2000-10-06       Impact factor: 5.157

4.  Analysis of the C-terminal membrane anchor domains of hepatitis C virus glycoproteins E1 and E2: toward a topological model.

Authors:  Benoit Charloteaux; Laurence Lins; Henri Moereels; Robert Brasseur
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

5.  Functional analysis of hepatitis C virus E2 glycoproteins and virus-like particles reveals structural dissimilarities between different forms of E2.

Authors:  Ania Owsianka; Reginald F Clayton; Lawrence D Loomis-Price; Jane A McKeating; Arvind H Patel
Journal:  J Gen Virol       Date:  2001-08       Impact factor: 3.891

6.  The transmembrane domain of the hepatitis C virus E2 glycoprotein is required for correct folding of the E1 glycoprotein and native complex formation.

Authors:  J Patel; A H Patel; J McLauchlan
Journal:  Virology       Date:  2001-01-05       Impact factor: 3.616

7.  Human monoclonal antibodies that inhibit binding of hepatitis C virus E2 protein to CD81 and recognize conserved conformational epitopes.

Authors:  K G Hadlock; R E Lanford; S Perkins; J Rowe; Q Yang; S Levy; P Pileri; S Abrignani; S K Foung
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

8.  Construction and characterization of chimeric hepatitis C virus E2 glycoproteins: analysis of regions critical for glycoprotein aggregation and CD81 binding.

Authors:  Arvind H Patel; Jonny Wood; Francois Penin; Jean Dubuisson; J A McKeating
Journal:  J Gen Virol       Date:  2000-12       Impact factor: 3.891

9.  Binding of hepatitis C virus-like particles derived from infectious clone H77C to defined human cell lines.

Authors:  Sabine Wellnitz; Bettina Klumpp; Heidi Barth; Susumu Ito; Erik Depla; Jean Dubuisson; Hubert E Blum; Thomas F Baumert
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

Review 10.  Recent advances in the molecular biology of hepatitis C virus.

Authors:  S Rosenberg
Journal:  J Mol Biol       Date:  2001-10-26       Impact factor: 5.469

View more
  77 in total

1.  Endogenous virus and hepatitis C virus-like particle budding in BHK-21 cells.

Authors:  Emmanuelle Blanchard; Denys Brand; Philippe Roingeard
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

2.  Conformational changes in the herpes simplex virus ICP8 DNA-binding protein coincident with assembly in viral replication structures.

Authors:  Susan L Uprichard; David M Knipe
Journal:  J Virol       Date:  2003-07       Impact factor: 5.103

3.  Structural analysis of hepatitis C virus core-E1 signal peptide and requirements for cleavage of the genotype 3a signal sequence by signal peptide peptidase.

Authors:  Verena Oehler; Ana Filipe; Roland Montserret; Daniel da Costa; Gaie Brown; François Penin; John McLauchlan
Journal:  J Virol       Date:  2012-05-16       Impact factor: 5.103

Review 4.  Molecular biology of hepatitis C virus.

Authors:  Tetsuro Suzuki; Hideki Aizaki; Kyoko Murakami; Ikuo Shoji; Takaji Wakita
Journal:  J Gastroenterol       Date:  2007-06-29       Impact factor: 7.527

5.  Basic residues in hypervariable region 1 of hepatitis C virus envelope glycoprotein e2 contribute to virus entry.

Authors:  Nathalie Callens; Yann Ciczora; Birke Bartosch; Ngoc Vu-Dac; François-Loïc Cosset; Jean-Michel Pawlotsky; François Penin; Jean Dubuisson
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

6.  CD81-dependent binding of hepatitis C virus E1E2 heterodimers.

Authors:  Laurence Cocquerel; Chiung-Chi Kuo; Jean Dubuisson; Shoshana Levy
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

7.  Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein.

Authors:  Ania Owsianka; Alexander W Tarr; Vicky S Juttla; Dimitri Lavillette; Birke Bartosch; François-Loïc Cosset; Jonathan K Ball; Arvind H Patel
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

8.  Hepatitis C virus (HCV) infection may elicit neutralizing antibodies targeting epitopes conserved in all viral genotypes.

Authors:  Nicasio Mancini; Roberta A Diotti; Mario Perotti; Giuseppe Sautto; Nicola Clementi; Giovanni Nitti; Arvind H Patel; Jonathan K Ball; Massimo Clementi; Roberto Burioni
Journal:  PLoS One       Date:  2009-12-11       Impact factor: 3.240

9.  Identification of GBF1 as a cellular factor required for hepatitis C virus RNA replication.

Authors:  Lucie Goueslain; Khaled Alsaleh; Pauline Horellou; Philippe Roingeard; Véronique Descamps; Gilles Duverlie; Yann Ciczora; Czeslaw Wychowski; Jean Dubuisson; Yves Rouillé
Journal:  J Virol       Date:  2009-11-11       Impact factor: 5.103

10.  The hypervariable region 1 of the E2 glycoprotein of hepatitis C virus binds to glycosaminoglycans, but this binding does not lead to infection in a pseudotype system.

Authors:  Arnab Basu; Aster Beyene; Keith Meyer; Ranjit Ray
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.